Indications: Flibanserin (Addyi) is approved for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty.
Dosing: Recommended dosage is 100 mg taken once daily at bedtime. Discontinue treatment after 8 weeks if no improvement.
Pharmacokinetics: Flibanserin showed dose-proportional pharmacokinetics for Cmax after single oral doses of 100 mg to 250 mg (the recommended and 2.5 times the recommended dosage, respectively) in healthy female subjects. Steady state was achieved after 3 days of dosing. The extent of exposure with once-daily dosing of 100 mg of flibanserin was increased 1.4-fold as compared to a single dose.
Effectiveness: In clinical trials, treatment with flibanserin increased the number of satisfying sexual events by 0.5 to 1 additional event per month over placebo, increased the sexual desire score by 0.3 to 0.4 over placebo, and decreased the distress score related to sexual desire by 0.3 to 0.4 over placebo.
Side Effects/Risks: The most common adverse reactions are dizziness, somnolence (sleepiness), nausea, fatigue, insomnia and dry mouth.
More Information: Addyi is not indicated for HSDD due to a co-existing medical or psychiatric condition, problems within a relationship, or the effects of a medication or other drug substance.
Source: Highlights of Prescribing Information: Addyi. U.S. Food & Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526Orig1s000lbl.pdf. Revised August 2015. Accessed August 19, 2015.
This Week's Must Reads
Antibiotic Use Among US Older Adults, BMJ; ePub 2018 Jul 27; Olesen, Barnett, et al
Healthy Behaviors & Reduced Risk of Obesity , Mayo Clin Proc; ePub 2018 Jul 27; Shook, et al
Modifiable Risk Factors in New BP Categories, Am J Med; ePub 2018 Jul 26; Gu, Yue, et al
Psychological Screening for Youth with Abdominal Pain, Pediatrics; ePub 2018 Jul 25; Cunningham, et al
Low-Calorie Sweetened Beverages & Cardiometabolic Health, Circulation; ePub 2018 Jul 30; Johnson, et al
Must Reads in Women's Health
Acute Myocardial Infarction During Pregnancy, Mayo Clin Proc; ePub 2018 Jul 18; Smilowitz, et al
Evaluating ASCVD Risks Among US Women, JAMA Intern Med; ePub 2018 Jul 23; Mora, et al
Hypertensive Disorders of Pregnancy & CVD Risk, Ann Intern Med; ePub 2018 Jul 3; Stuart, et al
Chocolate Intake & Incident CHD in Women , Am J Clin Nutrit; ePub 2018 Jun 21; Greenberg, et al
Maternal Loss of Control Over Eating, Am J Clin Nutr; ePub 2018 Jun 5; Micali, et al